Organization (Industry)
A.S. Watson (Netherlands)
ClinicalTrials.gov lists A.S. Watson (Netherlands) as lead sponsor of 30 trials. It has 16 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo A.S. Watson Group, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers A.S. Watson (Netherlands): 30 lead-sponsored trials and 1 legal-entity registration.
Disease areas (30)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Anemia | 9 |
| Iron Deficiencies | 8 |
| Anemia, Iron-Deficiency | 6 |
| Kidney Failure, Chronic | 5 |
| Renal Insufficiency, Chronic | 5 |
Showing 5 of 30 disease areas.
Trials by start year as sponsor or collaborator (12)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2013 | 1 |
| 2012 | 3 |
| 2011 | 1 |
| 2010 | 4 |
| 2009 | 3 |
| 2008 | 2 |
| 2007 | 2 |
| 2006 | 2 |
| 2005 | 5 |
| 2004 | 4 |
Showing 10 of 12 years.
Recruitment duration, a model prediction: none of the 30 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (16)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Sodium Ferric Gluconate Complex in Sucrose. | 4 |
| Ferrous Sulfate Tablets | 2 |
| Sodium Ferric Gluconate Complex in Sucrose Injection | 2 |
| oxybutynin transdermal delivery system (Oxytrol(r)) | 1 |
| Ferric Gluconate | 1 |
Showing 5 of 16 approved assets.
Journals published in (26)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Journal of urology | 5 |
| Fertility and sterility | 4 |
| Kidney international | 3 |
| Journal of the American Society of Nephrology : JASN | 2 |
| Urology | 2 |
Showing 5 of 26 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 34 | 2 | 2023-08-15 |
FDA recalls (1)
| Product | Classification | Initiated |
|---|---|---|
| Taztia XT(diltiazem HCI extended release capsules, USP, Once-A-Day Dosage, 360 mg, 90 Capsules per bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, Distributed by: Watson Pharma, NDC 62037-700-90. | Class II | 2012-12-18 |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| Eastern Virginia Medical School | Co sponsors trial with | 1 |
Latest dated events (72)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2023-08-15 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2022-08-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2021-01-12 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2016-02-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2015-12-01 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 72 events.
Biomarker capability evidence (29)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| EPO | Trial sponsor | Named in trial inclusion criteria |
| EPO | Trial sponsor | Named in trial inclusion criteria |
| EPO | Trial sponsor | Named in trial inclusion criteria |
| EPO | Trial sponsor | Named in trial inclusion criteria |
| EPX | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 29 evidence rows.
On Scientist.com
A.S. Watson (Netherlands) is listed as a research supplier in the Scientist.com network.
Watson is one of the highest quality suppliers of products and services geared towards enhancing human health and nutrition around the world. We are a leader in developing quality products and ingredient systems for the food, and supplement industries. Expertise in microencapsulation, agglomeration, micronizing, spray drying, and film technology allow us to develop unique formulations and products using Watson manufactured value-added ingredients.
- Website
- www.watson-inc.com
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sponsor delivery record, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Watson Inc on Scientist.com
For prices, more details, or to contact Watson Inc, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.